We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Affirms Sickle Cell Disease Gene Therapies Cost-Effective at $2 Million
ICER Affirms Sickle Cell Disease Gene Therapies Cost-Effective at $2 Million
A revised report from the Institute for Clinical Evaluation and Research (ICER) has reiterated that two experimental gene therapies for sickle cell disease (SCD) would likely be cost-effective if priced at $2 million.